Index - P/E 668.34 EPS (ttm) 0.25 Insider Own 7.02% Shs Outstand 55.77M Perf Week 2.73%
Market Cap 9.43B Forward P/E 83.97 EPS next Y 2.01 Insider Trans -0.74% Shs Float 51.95M Perf Month -3.08%
Income 14.84M PEG 39.06 EPS next Q 0.33 Inst Own 104.63% Short Float 8.83% Perf Quarter -15.87%
Sales 607.45M P/S 15.52 EPS this Y -16.94% Inst Trans 1.47% Short Ratio 9.18 Perf Half Y 12.19%
Book/sh 35.29 P/B 4.78 EPS next Y 38.21% ROA 0.55% Short Interest 4.59M Perf Year 5.33%
Cash/sh 13.97 P/C 12.08 EPS next 5Y 17.11% ROE 0.76% 52W Range 110.45 - 211.13 Perf YTD -6.18%
Dividend Est. - P/FCF 86.05 EPS past 5Y 15.08% ROI 0.56% 52W High -20.10% Beta 1.07
Dividend TTM - Quick Ratio 5.24 Sales past 5Y 31.42% Gross Margin 42.41% 52W Low 52.73% ATR (14) 6.31
Dividend Ex-Date - Current Ratio 6.35 EPS Y/Y TTM -91.17% Oper. Margin 5.52% RSI (14) 47.92 Volatility 4.59% 3.68%
Employees 1783 Debt/Eq 0.37 Sales Y/Y TTM -21.90% Profit Margin 2.44% Recom 1.50 Target Price 204.80
Option/Short Yes / Yes LT Debt/Eq 0.33 EPS Q/Q -92.68% Payout 0.00% Rel Volume 1.00 Prev Close 168.04
Sales Surprise -3.30% EPS Surprise -6.98% Sales Q/Q -17.14% Earnings May 01 BMO Avg Volume 499.72K Price 168.69
SMA20 1.31% SMA50 -6.54% SMA200 -1.30% Trades
Volume 201,154 Change 0.39%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-04-23 Downgrade The Benchmark Company
Buy → Hold
Jul-20-23 Initiated Wells Fargo
Overweight
$185
Jul-05-23 Resumed JP Morgan
Overweight
$220
Mar-28-23 Initiated The Benchmark Company
Buy
$230
Dec-14-22 Initiated Deutsche Bank
Hold
$180
Dec-07-22 Initiated RBC Capital Mkts
Sector Perform
$190
Jul-20-22 Initiated UBS
Buy
$213
Oct-14-21 Initiated Exane BNP Paribas
Outperform
$330
Nov-10-20 Initiated KeyBanc Capital Markets
Overweight
$241
Aug-24-20 Reiterated H.C. Wainwright
Buy
$151 → $168
Jun-30-20 Reiterated H.C. Wainwright
Buy
$143 → $151
May-07-20 Reiterated H.C. Wainwright
Buy
$100 → $143
Mar-23-20 Reiterated H.C. Wainwright
Buy
$110 → $100
Nov-15-19 Initiated Stifel
Buy
Nov-01-19 Upgrade First Analysis Sec
Outperform → Strong Buy
$107 → $110
Oct-15-19 Initiated SVB Leerink
Outperform
$100
Aug-28-19 Reiterated First Analysis Sec
Outperform
$95 → $107
Aug-23-19 Resumed Stephens
Overweight
Jul-22-19 Upgrade H.C. Wainwright
Neutral → Buy
$110
Dec-17-18 Upgrade CL King
Neutral → Buy
Show Previous Ratings
Today 07:30AM
May-02-24 11:31AM
11:31AM
11:23AM
03:06AM
11:53AM
Loading…
May-01-24 11:53AM
09:11AM
08:50AM
08:47AM
07:47AM
(Associated Press Finance)
07:30AM
Apr-23-24 11:43AM
Apr-17-24 07:30AM
Apr-12-24 10:07AM
09:49AM
07:30AM
Loading…
Mar-19-24 07:30AM
Mar-12-24 01:18AM
Feb-27-24 02:02AM
Feb-24-24 12:03AM
Feb-22-24 11:24AM
10:39AM
Feb-21-24 08:45AM
08:12AM
07:51AM
(Associated Press Finance)
07:30AM
Feb-07-24 07:30AM
Jan-31-24 12:10PM
Jan-29-24 05:09AM
Dec-19-23 07:30AM
Dec-18-23 04:49AM
07:30AM
Loading…
Dec-07-23 07:30AM
Nov-30-23 11:31AM
Nov-15-23 07:15AM
Nov-14-23 02:01PM
07:30AM
Nov-07-23 07:30AM
Nov-02-23 07:30AM
Nov-01-23 12:10PM
11:46AM
12:04AM
(Thomson Reuters StreetEvents)
Oct-31-23 09:41AM
09:12AM
08:50AM
07:41AM
(Associated Press Finance)
07:30AM
Oct-25-23 10:01AM
Oct-24-23 10:00AM
Oct-17-23 11:44AM
07:30AM
Oct-02-23 07:30AM
Sep-27-23 06:51AM
Sep-26-23 12:41PM
(American City Business Journals)
07:30AM
Sep-14-23 10:10AM
Sep-12-23 07:30AM
Sep-06-23 03:06AM
Sep-01-23 12:19PM
11:31AM
07:30AM
Aug-21-23 06:53AM
Aug-17-23 08:00AM
Aug-10-23 09:39AM
Aug-09-23 06:10AM
Aug-03-23 11:19AM
Aug-02-23 08:55AM
07:49AM
07:30AM
Jul-31-23 09:08AM
Jul-26-23 10:02AM
Jul-25-23 11:40AM
Jul-20-23 10:01AM
Jul-19-23 07:30AM
Jul-10-23 08:34AM
Jun-30-23 10:54AM
Jun-21-23 08:00PM
Jun-07-23 11:30AM
Jun-02-23 11:31AM
Jun-01-23 11:31AM
May-31-23 07:30AM
May-30-23 12:09PM
May-09-23 05:52PM
May-03-23 01:20PM
May-02-23 11:36PM
(Thomson Reuters StreetEvents)
08:55AM
07:52AM
07:30AM
07:02AM
May-01-23 07:43AM
Apr-26-23 08:00PM
10:02AM
Apr-25-23 02:07PM
10:01AM
Apr-18-23 07:30AM
Apr-11-23 02:41PM
Mar-24-23 11:30AM
Mar-14-23 07:30AM
Feb-23-23 06:28PM
01:41PM
05:54AM
Feb-22-23 08:55AM
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
KURIYEL RALF Senior VP, R&D Mar 11 '24 Option Exercise 86.10 1,271 109,433 27,777 Mar 12 08:24 PM KURIYEL RALF Senior VP, R&D Mar 11 '24 Sale 193.73 3,517 681,348 24,260 Mar 12 08:24 PM Hunt Anthony Chief Executive Officer Mar 08 '24 Option Exercise 16.55 1 17 201,956 Mar 11 07:43 PM Hunt Anthony Chief Executive Officer Mar 08 '24 Sale 197.44 16,707 3,298,632 185,249 Mar 11 07:43 PM DAWES KAREN A Director Feb 27 '24 Option Exercise 42.07 4,626 194,616 88,367 Feb 28 09:56 PM DAWES KAREN A Director Feb 27 '24 Sale 193.35 1,000 193,350 87,367 Feb 28 09:56 PM Bylund James Chief Operating Officer Feb 23 '24 Option Exercise 94.33 940 88,670 18,508 Feb 26 08:38 PM Bylund James Chief Operating Officer Feb 23 '24 Sale 198.08 4,373 866,204 14,135 Feb 26 08:38 PM Gebski Christine See Remarks Nov 10 '23 Sale 147.13 3,788 557,328 28,787 Nov 13 05:10 PM DAWES KAREN A Director Aug 29 '23 Option Exercise 18.12 7,392 133,943 84,591 Aug 30 04:06 PM DAWES KAREN A Director Aug 29 '23 Sale 171.38 850 145,673 83,741 Aug 30 04:06 PM Madaus Martin D Director May 08 '23 Buy 156.18 500 78,090 1,611 May 08 09:15 PM
Index RUT P/E - EPS (ttm) -3.35 Insider Own 4.36% Shs Outstand 57.56M Perf Week 40.77%
Market Cap 2.56B Forward P/E - EPS next Y -2.53 Insider Trans -0.56% Shs Float 55.69M Perf Month 33.34%
Income -192.14M PEG - EPS next Q -0.77 Inst Own 112.82% Short Float 22.00% Perf Quarter 18.91%
Sales 277.49M P/S 9.23 EPS this Y 17.01% Inst Trans 2.39% Short Ratio 13.00 Perf Half Y 135.59%
Book/sh 9.63 P/B 4.56 EPS next Y 15.17% ROA -24.68% Short Interest 12.25M Perf Year 241.05%
Cash/sh 5.04 P/C 8.73 EPS next 5Y - ROE -30.40% 52W Range 11.81 - 44.90 Perf YTD 19.27%
Dividend Est. - P/FCF - EPS past 5Y -6.09% ROI -30.26% 52W High -2.09% Beta 1.76
Dividend TTM - Quick Ratio 5.06 Sales past 5Y 60.13% Gross Margin 38.29% 52W Low 272.24% ATR (14) 2.36
Dividend Ex-Date - Current Ratio 5.51 EPS Y/Y TTM 11.09% Oper. Margin -68.89% RSI (14) 75.75 Volatility 9.69% 5.99%
Employees 919 Debt/Eq 0.16 Sales Y/Y TTM 21.79% Profit Margin -69.24% Recom 1.80 Target Price 43.38
Option/Short Yes / Yes LT Debt/Eq 0.13 EPS Q/Q 24.44% Payout - Rel Volume 1.67 Prev Close 44.67
Sales Surprise 6.51% EPS Surprise 3.15% Sales Q/Q 25.13% Earnings May 02 AMC Avg Volume 942.34K Price 43.96
SMA20 37.57% SMA50 28.40% SMA200 57.25% Trades
Volume 628,863 Change -1.59%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-17-24 Upgrade Goldman
Neutral → Buy
$25 → $45
Sep-27-23 Initiated Berenberg
Buy
$27
Jan-05-23 Initiated Scotiabank
Sector Outperform
$33
Jan-03-23 Upgrade Evercore ISI
In-line → Outperform
$28 → $36
Mar-02-22 Resumed Cowen
Outperform
Oct-15-21 Resumed Cowen
Outperform
Jun-29-21 Initiated William Blair
Outperform
Jun-04-21 Initiated Goldman
Neutral
$110
Apr-12-21 Initiated Piper Sandler
Overweight
$150
Feb-05-21 Downgrade JP Morgan
Neutral → Underweight
$100
Jan-04-21 Downgrade Evercore ISI
Outperform → In-line
Oct-20-20 Initiated SVB Leerink
Mkt Perform
$90
May-31-19 Initiated Evercore ISI
Outperform
Nov-26-18 Initiated JP Morgan
Neutral
$27
Show Previous Ratings
May-03-24 03:55PM
01:58PM
01:22PM
10:02AM
06:47AM
(Thomson Reuters StreetEvents)
04:05AM
Loading…
04:05AM
May-02-24 09:00PM
05:35PM
04:33PM
(Associated Press Finance)
04:05PM
Apr-30-24 03:20PM
Apr-25-24 11:31AM
Apr-18-24 08:00AM
Mar-28-24 08:00AM
Mar-05-24 08:00AM
08:00AM
Loading…
Feb-22-24 08:00AM
Feb-13-24 01:59PM
Feb-10-24 05:28AM
Feb-07-24 08:00AM
Feb-06-24 08:05AM
08:00AM
Feb-05-24 08:09AM
08:00AM
Feb-02-24 11:42PM
(Thomson Reuters StreetEvents) +10.01%
07:55AM
07:36AM
(Associated Press Finance)
07:30AM
Jan-24-24 08:00AM
Jan-16-24 08:00AM
Jan-08-24 08:00AM
08:00AM
Loading…
Jan-05-24 08:00AM
Dec-19-23 12:44PM
Dec-18-23 08:00AM
Dec-15-23 08:11AM
Nov-20-23 08:55AM
Nov-18-23 01:29AM
(Thomson Reuters StreetEvents)
Nov-17-23 04:03PM
(Investor's Business Daily) +25.90%
08:40AM
08:28AM
07:47AM
(Associated Press Finance)
07:30AM
Nov-14-23 08:00AM
Nov-13-23 08:00AM
Nov-08-23 08:00AM
Nov-02-23 04:05PM
Oct-31-23 08:00AM
Oct-16-23 10:43AM
Oct-06-23 12:08PM
11:44AM
Oct-05-23 08:00AM
Oct-03-23 08:00AM
Sep-27-23 08:00AM
Sep-26-23 01:02PM
12:40PM
Sep-20-23 12:11PM
Sep-14-23 12:56PM
12:31PM
Sep-05-23 08:00AM
Aug-31-23 03:10AM
03:00AM
Aug-22-23 08:00AM
Aug-11-23 01:39PM
Aug-07-23 09:53AM
08:00AM
Aug-04-23 01:21PM
08:45AM
07:37AM
07:30AM
Jul-20-23 08:00AM
Jul-18-23 09:50AM
08:00AM
Jun-26-23 08:10AM
Jun-20-23 08:00AM
Jun-04-23 09:46AM
May-31-23 08:00AM
May-24-23 08:00AM
May-23-23 08:00AM
May-22-23 08:00AM
May-14-23 04:05PM
May-10-23 08:00AM
May-08-23 08:54AM
May-07-23 01:18PM
May-05-23 11:02AM
08:45AM
07:30AM
May-03-23 08:45AM
May-02-23 05:53AM
Apr-28-23 10:00AM
Apr-27-23 08:00AM
Apr-26-23 02:10PM
Apr-25-23 10:00AM
06:35AM
Apr-20-23 06:24PM
08:00AM
Apr-13-23 08:00AM
07:59AM
Mar-29-23 04:20PM
08:00AM
Mar-28-23 08:03AM
(Simply Wall St.) -10.32%
Mar-09-23 08:00AM
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Finn Patrick John President and COO Apr 23 '24 Sale 30.12 2,174 65,483 176,206 Apr 25 04:05 PM Laponis Adam Chief Financial Officer Apr 09 '24 Sale 33.16 556 18,434 74,444 Apr 11 04:05 PM Leproust Emily M. Chief Executive Officer Apr 02 '24 Sale 32.74 1,132 37,057 514,149 Apr 04 04:05 PM Finn Patrick John President and COO Apr 02 '24 Sale 32.74 492 16,106 178,380 Apr 04 04:05 PM Banyai William See Remark Apr 02 '24 Sale 32.74 327 10,705 345,986 Apr 04 04:05 PM Green Paula SVP of Human Resources Apr 02 '24 Sale 32.74 229 7,497 92,421 Apr 04 04:05 PM Cho Dennis See Remarks Apr 02 '24 Sale 32.74 129 4,223 81,004 Apr 04 04:05 PM Leproust Emily M. Chief Executive Officer Mar 20 '24 Sale 33.52 1,128 37,806 515,281 Mar 22 04:05 PM Banyai William See Remark Mar 20 '24 Sale 33.52 442 14,814 346,313 Mar 22 04:05 PM Cho Dennis See Remarks Mar 20 '24 Sale 33.52 230 7,709 81,133 Mar 22 04:05 PM Green Paula SVP of Human Resources Mar 20 '24 Sale 33.52 200 6,703 92,650 Mar 22 04:05 PM Cho Dennis See Remarks Mar 14 '24 Sale 34.60 93 3,218 81,363 Mar 18 04:05 PM Leproust Emily M. Chief Executive Officer Mar 06 '24 Sale 37.43 1,487 55,658 516,409 Mar 08 04:05 PM Green Paula SVP of Human Resources Mar 06 '24 Sale 37.43 600 22,458 92,850 Mar 08 04:05 PM Banyai William See Remark Mar 06 '24 Sale 37.43 549 20,549 346,755 Mar 08 04:05 PM Cho Dennis See Remarks Mar 06 '24 Sale 37.43 272 10,181 81,456 Mar 08 04:05 PM WERNER ROBERT F. Chief Accounting Officer Mar 06 '24 Sale 37.43 181 6,775 43,680 Mar 08 04:05 PM CHESS ROBERT Director Feb 08 '24 Sale 34.98 4,110 143,784 64,169 Feb 09 04:10 PM THORBURN JAMES M Chief Financial Officer May 23 '23 Option Exercise 11.59 13,324 154,425 62,042 May 25 04:05 PM Cho Dennis See Remarks May 10 '23 Buy 13.20 10,000 132,000 29,297 May 12 04:05 PM
Index RUT P/E - EPS (ttm) -1.07 Insider Own 27.56% Shs Outstand 32.52M Perf Week -1.58%
Market Cap 185.02M Forward P/E - EPS next Y -0.96 Insider Trans -0.71% Shs Float 23.89M Perf Month -14.87%
Income -34.78M PEG - EPS next Q -0.33 Inst Own 61.55% Short Float 5.15% Perf Quarter -24.09%
Sales 50.73M P/S 3.65 EPS this Y 1.42% Inst Trans 3.50% Short Ratio 7.02 Perf Half Y -14.74%
Book/sh 4.77 P/B 1.18 EPS next Y 13.64% ROA -17.04% Short Interest 1.23M Perf Year -20.87%
Cash/sh 4.07 P/C 1.38 EPS next 5Y - ROE -20.61% 52W Range 4.85 - 12.51 Perf YTD -50.00%
Dividend Est. - P/FCF - EPS past 5Y -31.19% ROI -21.70% 52W High -55.16% Beta 1.02
Dividend TTM - Quick Ratio 7.53 Sales past 5Y 21.26% Gross Margin 46.13% 52W Low 15.67% ATR (14) 0.37
Dividend Ex-Date - Current Ratio 8.37 EPS Y/Y TTM 7.26% Oper. Margin -83.26% RSI (14) 37.15 Volatility 7.26% 6.36%
Employees 230 Debt/Eq 0.03 Sales Y/Y TTM 5.62% Profit Margin -68.56% Recom 1.00 Target Price 15.33
Option/Short Yes / Yes LT Debt/Eq 0.02 EPS Q/Q 14.87% Payout - Rel Volume 0.44 Prev Close 5.62
Sales Surprise 7.52% EPS Surprise 8.84% Sales Q/Q 5.31% Earnings Apr 30 BMO Avg Volume 175.20K Price 5.61
SMA20 -3.47% SMA50 -13.30% SMA200 -18.59% Trades
Volume 30,746 Change -0.18%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-07-23 Initiated Stephens
Overweight
$14
Oct-15-21 Resumed Cowen
Outperform
Jan-12-21 Initiated William Blair
Outperform
Jan-12-21 Initiated SVB Leerink
Outperform
$70
Jan-12-21 Initiated Stifel
Buy
$65
Jan-12-21 Initiated Cowen
Outperform
May-01-24 08:49AM
03:09AM
12:08AM
(Thomson Reuters StreetEvents)
Apr-30-24 11:53AM
09:35AM
08:55AM
Loading…
08:55AM
07:45AM
07:30AM
Apr-23-24 07:00AM
Mar-12-24 07:00AM
Mar-07-24 12:02PM
Mar-05-24 07:33AM
07:00AM
Feb-29-24 07:00AM
Feb-22-24 07:00AM
07:00AM
Loading…
Feb-20-24 07:00AM
Feb-02-24 11:01PM
Dec-28-23 12:00PM
Dec-27-23 10:30AM
Dec-22-23 01:01PM
Dec-19-23 09:55AM
Dec-18-23 05:34AM
Nov-14-23 07:00AM
Nov-09-23 03:37PM
Nov-07-23 08:14AM
07:00AM
Nov-06-23 04:30PM
Oct-31-23 07:00AM
Oct-24-23 04:30PM
07:00AM
07:00AM
Loading…
Sep-26-23 07:00AM
Sep-18-23 07:00AM
Sep-15-23 07:00AM
Aug-26-23 07:50AM
Aug-08-23 09:15AM
07:00AM
Aug-07-23 07:00AM
Jul-31-23 07:00AM
Jul-25-23 07:00AM
Jul-16-23 08:42AM
Jul-13-23 05:42AM
May-30-23 07:00AM
May-23-23 09:54AM
07:00AM
May-09-23 08:25AM
07:00AM
May-04-23 07:00AM
Apr-26-23 07:00AM
Apr-25-23 07:00AM
Apr-18-23 11:14AM
Mar-08-23 02:22AM
(Thomson Reuters StreetEvents)
Mar-07-23 08:25AM
07:00AM
Feb-27-23 06:05PM
Feb-21-23 07:00AM
Feb-14-23 07:00AM
Feb-07-23 01:37PM
Feb-06-23 05:16AM
Jan-17-23 07:00AM
Dec-29-22 06:02AM
Dec-07-22 07:00AM
Nov-16-22 06:24AM
Nov-14-22 11:44AM
10:05AM
07:00AM
Nov-10-22 07:00AM
Nov-09-22 07:00AM
Nov-02-22 07:00AM
Oct-19-22 07:00AM
Oct-12-22 05:00PM
Sep-29-22 07:50AM
Aug-09-22 04:00PM
08:45AM
07:30AM
07:00AM
Jul-27-22 07:00AM
Jul-25-22 07:21AM
Jul-19-22 07:00AM
Jun-13-22 04:22PM
Jun-02-22 07:00AM
May-26-22 07:00AM
May-11-22 02:30AM
May-10-22 08:15AM
07:00AM
May-09-22 07:00AM
May-03-22 07:00AM
Apr-21-22 07:00AM
Apr-12-22 05:37PM
07:00AM
Mar-08-22 05:58PM
Mar-07-22 10:30PM
05:15PM
04:05PM
Mar-02-22 04:30PM
Feb-15-22 07:00AM
Feb-14-22 12:24PM
Feb-08-22 07:00AM
Jan-21-22 11:37AM
Jan-09-22 07:00PM
Jan-07-22 07:00AM
908 Devices, Inc. engages in the development of measurement devices for chemical and biochemical analysis. It offers products using mass spectrometry technology, an analytical technique for measuring the mass of charged molecules that is used in chemical analysis laboratories for applications, such as safety and security, food science, biotechnology, clinical diagnostics, and controlling industrial processes. Its products include desktops and handhelds. The company was founded by Kevin J. Knopp, Miller Scott, Steve Araiza, Andrew Bartfay, Michael Jobin, Christopher D. Brown, and Christopher J. Petty in 2012 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Knopp Kevin J. President and CEO Apr 16 '24 Option Exercise 1.75 47,000 82,250 458,981 Apr 16 04:11 PM Brown Christopher D. Chief Product Officer Apr 01 '24 Option Exercise 1.75 3,600 6,300 884,994 Apr 02 04:06 PM Griffith Joseph H. IV Chief Financial Officer Mar 26 '24 Option Exercise 1.58 8,437 13,330 93,437 Mar 27 04:16 PM Griffith Joseph H. IV Chief Financial Officer Feb 02 '24 Sale 7.09 9,711 68,873 80,000 Feb 02 07:10 PM Knopp Kevin J. President and CEO Feb 01 '24 Sale 7.00 9,071 63,461 411,981 Feb 02 04:39 PM Griffith Joseph H. IV Chief Financial Officer Feb 01 '24 Sale 7.00 5,698 39,892 89,711 Feb 02 07:10 PM Turner Michael S. Chief Legal & Admin Officer Feb 01 '24 Sale 6.99 5,232 36,559 9,105 Feb 02 04:40 PM Brown Christopher D. Chief Product Officer Feb 01 '24 Sale 7.01 3,957 27,730 886,394 Feb 02 04:37 PM Griffith Joseph H. IV Chief Financial Officer Dec 28 '23 Sale 12.08 6,000 72,480 80,000 Jan 02 05:01 PM Brown Christopher D. Chief Product Officer Dec 21 '23 Sale 9.12 7,370 67,214 877,905 Dec 21 04:46 PM Brown Christopher D. Chief Product Officer Dec 20 '23 Sale 9.10 5,235 47,638 885,275 Dec 21 04:46 PM Brown Christopher D. Chief Product Officer Dec 19 '23 Sale 9.08 7,395 67,147 890,510 Dec 21 04:46 PM Griffith Joseph H. IV Chief Financial Officer Dec 19 '23 Sale 9.08 5,580 50,666 86,000 Dec 21 04:47 PM Brown Christopher D. Chief Product Officer Jun 07 '23 Sale 10.03 4,470 44,834 897,905 Jun 09 04:17 PM Knopp Kevin J. President and CEO Jun 05 '23 Option Exercise 1.75 28,500 49,875 396,348 Jun 05 04:07 PM Knopp Kevin J. President and CEO May 23 '23 Sale 10.12 60,000 607,200 367,848 May 25 04:08 PM Brown Christopher D. Chief Technology Officer May 23 '23 Sale 10.02 10,000 100,200 892,375 May 25 04:12 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
